期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

滤泡性淋巴瘤新药研究进展

Research progress on new agents for follicular iymphoma
原文传递
导出
摘要 滤泡性淋巴瘤（FL）是一种起源于B淋巴细胞的非霍奇金淋巴瘤（NHL），临床自然病程较长，表现惰性，初始治疗后易复发，传统的治疗方案多难以治愈。因此选择合适的治疗方案是延长患者生存时间的关键。利妥昔单抗、放射免疫治疗、苯达莫司汀等已被应用于FL的治疗。一些具有前景的新药如ofatumumab、依帕珠单抗（epratuzumab）、雷利度胺、硼替佐米、ABT-263等目前正在进行临床试验，这些新药将会为FL的治疗增加更多的选择。 Follicular lymphoma （FL） is a type of B lymphocytic non-Hodgkin lymphoma. Clinically, FL presents with long course, indolent behavior, and is characterized by prompt response to initial therapy but almost invariably subsequent relapses. It is considered incurable with conventional therapies. Appropriate treatment strategies are critical for survival. Recently, several drugs such as rituximab, and bendamustine have been approved for FL treatment. Very promising novel agents like ofatumumab, epratuzumab, lenalidomide, bortezomib and ABT-263 are now under investigation in clinical trials and will provide more choices for FL therapy.
作者 高珊（综述） 克晓燕（审校）
机构地区 北京大学第三医院血液科
出处 《白血病．淋巴瘤》 CAS 2011年第12期762-765,共4页 Journal of Leukemia & Lymphoma
关键词 淋巴瘤 滤泡型 淋巴瘤 非霍奇金 药物疗法 联合 Lymphoma, follicular Lymphoma, non-Hodgkin Drug therapy, combination
分类号 R733.4 [医药卫生—肿瘤]
  • 相关文献

参考文献32

  • 1Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oneol, 2005, 23: 8447-8452.
  • 2Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 2005, 106: 3725-3732.
  • 3Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol, 2005, 23: 694-704.
  • 4Luthy SK, Ng AK, Silver B, et al. Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma. Ann Oncol, 2008, 19: 2043-2047.
  • 5Jacobs SA, Swerdlow SH, Kant J, et al. Phase Ⅱ trial of short-course CHOP-R followed by ^90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res, 2008, 14: 7088-7094.
  • 6Kaminski MS, Tuck M, Estes J, et al. ^131Ⅰ-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med, 2005, 352: 441-449.
  • 7Barr PM, Lazarus HM. Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation. Curr Opin Oncol, 2008, 20: 502- 508.
  • 8杨艳梅,沈晓梅,史克倩,杨同华,王云娟,赖洵,李正发,闻艳,陆智强.自体外周血造血干细胞移植治疗非霍奇金淋巴瘤临床分析[J].白血病．淋巴瘤,2006,15(5):381-382. 被引量：5
  • 9Leoni LM, Bailey B, Reifert J, et al. Bendamustine displays a distinct pattern of cytoxicity and unique mechanistic features compared with other Alkylating agents. Clin Cancer Res, 2008, 14:309-317.
  • 10Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase Ⅱ multicenter, single-agent study. J Clin Oncol, 2008, 26: 204-210.

二级参考文献69

  • 1蔡宇,王椿,杨隽,颜式可,蔡琦,高彦荣,姜杰玲.抗CD_(20)单克隆抗体在非霍奇金淋巴瘤治疗中的应用[J].白血病．淋巴瘤,2005,14(3):145-147. 被引量：8
  • 2扶云碧,孙启鑫,孟凡义,谢军,周光飚.蛋白酶体抑制剂硼替佐米诱导髓系白血病细胞株 HL60凋亡的机制研究[J].中华医学杂志,2006,86(34):2413-2416. 被引量：14
  • 3Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MINT) Group[J]. Lancet Oncol, 2006, 7(5): 379- 391.
  • 4Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de I'Adulte[J]. J Clin Oncol, 2005, 23(18): 4117-4126.
  • 5Coiffier B, Feugier P, Mounier N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients[Meeting Abstracts][J]. J Clin Oncol, 2007, 25 (18S): 8009.
  • 6Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD 10 B-cell lymphomas: a randomized controlled trial (RICOVER-60)[J]. Lancet Oncol, 2008, 9(2): 105- 116.
  • 7Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and eyelophosphamide, doxorubicin, vineristine, and prednisoue significantly improves response and time to treatment failure, but not long-term outcome in patients with previouslyuntreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)[J]. J Clin Oncol, 2005, 23(9):1984-1992.
  • 8Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as firstline and maintenance therapy for patients with indolent non-Hodgkin's lymphoma[J]. J Clin Oncol, 2002, 20(20): 4261-4267.
  • 9Ghiehnini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly×4 schedule[J]. Blood, 2004, 103(12): 4416- 4423.
  • 10Gordan LN, Grow WB, Pusateri A, et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders[J]. J Clin Oncol, 2005, 23(6): 1096- 1102.

共引文献12

白血病．淋巴瘤
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部